X

colostrum-cd4-lymphocytes

Intensification Of Antiretroviral Therapy With Raltegravir Or Addition Of Hyperimmune Bovine Colostrum In HIV-infected Patients With Suboptimal CD4+ T-cell Response: A Randomized Controlled Trial

効果 なし
試験方法 二重盲検法
試験期間 1-6 ヶ月
被験者数 73
性別 男女
年齢 45-64
この研究の注釈:

Supplementation of 1,200mg colostrum (40% immunoglobulins) daily for 24 weeks in HIV infected persons on stable antiretroviral therapy (known to decrease CD4+ lymphocytes) failed to improve the suppressed lymphocytes relative to control. Serum HIV-RNA was also not affected by therapy.


ColoPlus, A New Product Based On Bovine Colostrum, Alleviates HIV-associated Diarrhoea
効果 増加
試験方法 コホート法
試験期間 2-4 週間
被験者数 30
性別 男女
年齢 18-29, 30-44, 45-64
この研究の注釈:

In HIV-infected persons with associated diarrhea, a colostrum containing porridge known as ColoPlus (32% colostrum, where each 50g pack contained 2-4g immunoglobulins and is taken twice daily) for four weeks was able to greatly reduce daily bowel movements from 7 down to 1.6, the benefit lasting for an additional two weeks after supplement cessation.

It was noted that CD4+ lymphocytes increased in all persons, to a larger degree in those with less than 200 cells per microliter (experiencing a 94-110% increase) and that fatigue associated with HIV was reduced 81%.


Effect Of A Mixture Of Micronutrients, But Not Of Bovine Colostrum Concentrate, On Immune Function Parameters In Healthy Volunteers: A Randomized Placebo-controlled Study
効果 なし
試験方法 二重盲検法
試験期間 1-6 ヶ月
被験者数 138
性別 男女
年齢 30-44, 45-64, 65+
体型 平均
この研究の注釈:

Supplementation of colostrum (1,200mg, conferring 500mg immunoglobulins) failed to appreciably influence various immune parameters and DTH responsiveness relative to placebo.


Effect Of Bovine Colostrum-based Food Supplement In The Treatment Of HIV-associated Diarrhea In Northern Uganda: A Randomized Controlled Trial
効果 増加
試験方法 二重盲検法
試験期間 2-4 週間
被験者数 97
性別 男女
年齢 18-29, 30-44, 45-64
体型 平均, Underweight
この研究の注釈:

50g of a colostrum containing porridge (twice daily) for four weeks to persons with HIV-associated diarrhea for four weeks (and followed up for an additional five) significantly reduced stool frequency 79% (58% in controls given standard anti-diarrhea therapy) and increased CD4+ lymphocytes 14% despite a 12% decrease in control. Fatigue was reported to be reduced by 85% relative to baseline, greater than the 43% reduction seen with placebo.


管理人 :慶應義塾大学の理工学部卒業後、国内外でコンサルティング業務やスタートアップの立ち上げを経験した後、日本に帰国してから健康・医療の情報を収集して発信しています。 趣味:ネットサーフィン、読書(最近かなり減ってますが)、アウトドア(家族と) 毎日メディテーションとジョギング、筋トレ・ストレッチしています。既婚で子供4人(男女女男)です。